Literature DB >> 10677522

The dual functions of fas ligand in the regulation of peripheral CD8+ and CD4+ T cells.

I Suzuki1, P J Fink.   

Abstract

Although Fas ligand (FasL) is well characterized for its capacity to deliver a death signal through its receptor Fas, recent work demonstrates that FasL also can receive signals facilitating antigen (Ag)-specific proliferation of CD8(+) T cells. The fact that the gld mutation differentially influences the proliferative capacity of CD8(+) and CD4(+) T cells presented the intriguing possibility that a single molecule may play opposing roles in these two subpopulations. The present study focuses on how these positive and negative regulatory roles are balanced. We show that naive CD4(+) T cells are responsive to FasL-mediated costimulation on encounter with Ag when Fas-mediated death is prevented. Thus, the machinery responsible for transducing the FasL positive reverse signal operates in both CD4(+) and CD8(+) T cells. Instead, differential control of FasL expression distinguishes the role of FasL in these two T cell subpopulations. FasL costimulation occurs immediately on T cell receptor ligation and correlates with the up-regulation of FasL expression on CD8(+) and naive CD4(+) T cells, both of which are sensitive to the FasL costimulatory signal. Conversely, FasL-initiated death occurs late in an immune response when high levels of FasL expression are maintained on CD4(+) T cells that are sensitive to Fas-mediated death, but not on CD8(+) T cells that are relatively insensitive to this signal. This careful orchestration of FasL expression during times of susceptibility to costimulation and conversely, to death, endows FasL with the capacity to both positively and negatively regulate the peripheral T cell compartment.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10677522      PMCID: PMC26500          DOI: 10.1073/pnas.97.4.1707

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  46 in total

1.  Differential ability of T cell subsets to undergo activation-induced cell death.

Authors:  A S Varadhachary; S N Perdow; C Hu; M Ramanarayanan; P Salgame
Journal:  Proc Natl Acad Sci U S A       Date:  1997-05-27       Impact factor: 11.205

2.  Release of preformed Fas ligand in soluble form is the major factor for activation-induced death of Jurkat T cells.

Authors:  M J Martínez-Lorenzo; M A Alava; A Anel; A Piñeiro; J Naval
Journal:  Immunology       Date:  1996-12       Impact factor: 7.397

3.  Polymorphism of murine Fas ligand that affects the biological activity.

Authors:  N Kayagaki; N Yamaguchi; F Nagao; S Matsuo; H Maeda; K Okumura; H Yagita
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-15       Impact factor: 11.205

4.  Surface T cell Fas receptor/CD95 regulation, in vivo activation, and apoptosis. Activation-induced death can occur without Fas receptor.

Authors:  C L Tucek-Szabo; S Andjelić; E Lacy; K B Elkon; J Nikolić-Zugić
Journal:  J Immunol       Date:  1996-01-01       Impact factor: 5.422

5.  Expansion or elimination of B cells in vivo: dual roles for CD40- and Fas (CD95)-ligands modulated by the B cell antigen receptor.

Authors:  J C Rathmell; S E Townsend; J C Xu; R A Flavell; C C Goodnow
Journal:  Cell       Date:  1996-10-18       Impact factor: 41.582

6.  The roles of Fas/APO-1 (CD95) and TNF in antigen-induced programmed cell death in T cell receptor transgenic mice.

Authors:  H K Sytwu; R S Liblau; H O McDevitt
Journal:  Immunity       Date:  1996-07       Impact factor: 31.745

7.  Lymphotoxin-beta receptor signaling complex: role of tumor necrosis factor receptor-associated factor 3 recruitment in cell death and activation of nuclear factor kappaB.

Authors:  T L VanArsdale; S L VanArsdale; W R Force; B N Walter; G Mosialos; E Kieff; J C Reed; C F Ware
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-18       Impact factor: 11.205

8.  Unequal death in T helper cell (Th)1 and Th2 effectors: Th1, but not Th2, effectors undergo rapid Fas/FasL-mediated apoptosis.

Authors:  X Zhang; T Brunner; L Carter; R W Dutton; P Rogers; L Bradley; T Sato; J C Reed; D Green; S L Swain
Journal:  J Exp Med       Date:  1997-05-19       Impact factor: 14.307

9.  Metalloproteinase-mediated release of human Fas ligand.

Authors:  N Kayagaki; A Kawasaki; T Ebata; H Ohmoto; S Ikeda; S Inoue; K Yoshino; K Okumura; H Yagita
Journal:  J Exp Med       Date:  1995-12-01       Impact factor: 14.307

10.  Fas and Fas ligand in embryos and adult mice: ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover.

Authors:  L E French; M Hahne; I Viard; G Radlgruber; R Zanone; K Becker; C Müller; J Tschopp
Journal:  J Cell Biol       Date:  1996-04       Impact factor: 10.539

View more
  29 in total

1.  Stimulation of FasL induces production of proinflammatory mediators through activation of mitogen-activated protein kinases and nuclear factor-κB in THP-1 cells.

Authors:  Sang-Min Lee; Eun-Ju Kim; Kyoungho Suk; Won-Ha Lee
Journal:  Inflammation       Date:  2012-02       Impact factor: 4.092

Review 2.  Death receptors and caspases: role in lymphocyte proliferation, cell death, and autoimmunity.

Authors:  Sabine Adam-Klages; Dieter Adam; Ottmar Janssen; Dieter Kabelitz
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

3.  Fas ligand enhances malignant behavior of tumor cells through interaction with Met, hepatocyte growth factor receptor, in lipid rafts.

Authors:  Huan-Ching Lin; Po-Yin Lai; Yu-ping Lin; Jyun-Yuan Huang; Bei-Chang Yang
Journal:  J Biol Chem       Date:  2012-04-25       Impact factor: 5.157

4.  Autoantibody production in lpr/lpr gld/gld mice reflects accumulation of CD4+ effector cells that are resistant to regulatory T cell activity.

Authors:  Brian D Hondowicz; Michele L Fields; Simone A Nish; Joseph Larkin; Andrew J Caton; Jan Erikson
Journal:  J Autoimmun       Date:  2008-06-09       Impact factor: 7.094

5.  Accelerated thymocyte maturation in IL-12Rβ2-deficient mice contributes to increased susceptibility to autoimmune inflammatory demyelination.

Authors:  B Gran; S Yu; G X Zhang; A Rostami
Journal:  Exp Mol Pathol       Date:  2010-06-30       Impact factor: 3.362

Review 6.  Rethinking peripheral T cell tolerance: checkpoints across a T cell's journey.

Authors:  Mohamed A ElTanbouly; Randolph J Noelle
Journal:  Nat Rev Immunol       Date:  2020-10-19       Impact factor: 53.106

7.  Fas ligand is required for the development of respiratory syncytial virus vaccine-enhanced disease.

Authors:  Matthew R Olson; Steven M Varga
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

8.  Abnormalities in the T and NK lymphocyte phenotype in patients with Nijmegen breakage syndrome.

Authors:  J Michałkiewicz; C Barth; K Chrzanowska; H Gregorek; M Syczewska; C M B Weemaes; K Madaliński; J Stachowski
Journal:  Clin Exp Immunol       Date:  2003-12       Impact factor: 4.330

9.  Acute cardiac allograft rejection by directly cytotoxic CD4 T cells: parallel requirements for Fas and perforin.

Authors:  Todd J Grazia; Robert J Plenter; Sarah M Weber; Helen M Lepper; Francisco Victorino; Martin R Zamora; Biagio A Pietra; Ronald G Gill
Journal:  Transplantation       Date:  2010-01-15       Impact factor: 4.939

10.  CD95 co-stimulation blocks activation of naive T cells by inhibiting T cell receptor signaling.

Authors:  Gudrun Strauss; Jonathan A Lindquist; Nathalie Arhel; Edward Felder; Sabine Karl; Tobias L Haas; Simone Fulda; Henning Walczak; Frank Kirchhoff; Klaus-Michael Debatin
Journal:  J Exp Med       Date:  2009-06-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.